{"groups":[{"description":"Participants with relapsed or refractory (r/r) B-cell indolent non-Hodgkin lymphoma (iNHL) subtype of follicular lymphoma (FL) received the following treatment during the study:\n\n* A conditioning chemotherapy regimen of fludarabine 30 mg/m\\^2/day intravenously (IV) and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3).\n* A single IV infusion at a target dose of 2×10\\^6 anti-cluster of differentiation 19 (CD19) chimeric antigen receptor (CAR) transduced autologous T cells/kg on Day 0.","id":"FG000","title":"Axicabtagene Ciloleucel (Follicular Lymphoma)"},{"description":"Participants with r/r B-cell iNHL subtype of marginal zone lymphoma (MZL) received the following treatment during the study:\n\n* A conditioning chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3).\n* A single IV infusion at a target dose of 2×10\\^6 anti-CD19 CAR transduced autologous T cells/kg on Day 0.","id":"FG001","title":"Axicabtagene Ciloleucel (Marginal Zone Lymphoma)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"61"},{"groupId":"FG001","numSubjects":"15"}],"type":"Rollover to Longterm Follow-up Study Criteria"},{"reasons":[{"groupId":"FG000","numSubjects":"40"},{"groupId":"FG001","numSubjects":"8"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"2"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"3"}],"type":"Subject Withdrawal of Consent from Further Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"}],"type":"Reason Not Specified"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}],"type":"Investigator Decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"127"},{"groupId":"FG001","numSubjects":"31"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"127"},{"groupId":"FG001","numSubjects":"31"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"189 participants were screened. A total of 159 participants were enrolled. However, one participant discontinued the study as the participant did not meet study condition eligibility criteria (was diagnosed with diffuse large B-cell lymphoma (DLBCL)). So, 158 participants were considered in the Full Analysis Set (FAS = all enrolled participants).","recruitmentDetails":"Participants were enrolled at study sites in the United States and France."}